Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LSI 2023: Intuitive Alums On Dawning Of Robotic Surgery To Digital OR Future

Executive Summary

Robotic surgery pioneer and co-founder of Intuitive Surgical Frederic Moll joined Daniel Hawkins, Intuitive’s first non-technical hire, for a discussion on the evolution of surgical robotics and outlook for the future.

You may also be interested in...



LSI 2023: What Ophthalmology Start-Ups Pitched To Investors At Emerging Medtech Summit

Leaders of burgeoning ophthalmology companies pitched innovations for treating glaucoma, macular degeneration and corneal blindness to potential investors and partners at the LSI Emerging Medtech Summit in Dana Point, CA. Here’s what Medtech Insight heard and learned in on-site interviews with chief executives.

Getting Personal With Avail Medsystems’ Daniel Hawkins Who Has Entrepreneurship In His Blood And Recipes For Businesses And Kitchens

Medtech Insight’s new series Getting Personal features conversations with new and veteran senior executives about their journeys to corporate leadership, their motivations, passions and the peaks and valleys of running a medtech company. Daniel Hawkins, founder and CEO of Avail Medsystems discussed how his company virtually connects health care professionals into the operating suite and allows for real-time collaboration.

Akili Introduces Adult Version Of Video Game Therapy To Lessen ADHD Symptoms

Video game therapy developer Akili Interactive launched a mobile video game therapy to reduce ADHD symptoms in adults. The company plans to seek FDA clearance.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel